Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
2024's Driving Clearing Robots: Master Suggestions and Surveys - 2Defense Minister Katz finally condemns Jewish extremist violence against Palestinians
- 3Holden Commodore Turbo BT1 Police Interceptor Offered for Sale in Australia
- 4The Force of Organic product: 10 Assortments That Improve Your Wellbeing
- 5Abbott issues US device correction for some glucose monitors over faulty readings risk
- Virtual reality opens doors for older people to build closer connections in real life
- Why do people have baby teeth and adult teeth?
- JFK's granddaughter Tatiana Schlossberg reveals terminal cancer diagnosis
- 'Crammed into a cell with vermin at New Year'
- Viable Correspondence: Building Solid Connections
- ISS astronaut snaps stunning nighttime photo of Florida and Cuba | Space photo of the day for Dec. 29, 2025
- Zelensky confidant dismissed from further posts amid bribery scandal
- Former United Launch Alliance CEO Tory Bruno joins competitor Blue Origin for national security projects
- Instructions to Construct an Organization While Chasing after a Web-based Degree
